Objective: The aim of the sutyd is to better understand the blonanserin population pharmacokinetic (PK) characteristics in Chinese healthy subjects.Methods: Data from two studies with fifty subjects were pooled to investigate the population PK characteristics of blonanserin at single-dose of4mg, 8mg and 12mg per oral under fasting, multi-dose of 4 mg bid or 8 mg qd for 7 days and under food intake condition with a single-dose of 8mg.Blonanserin plasma concentrations were detected using the LC/MS/MS.A nonlinear mixed-effects model (NO MEM) was developed to describe the blonanserin concentration-time profiles.Results: A two-compartment model with first-order absorption was built to describe the time-course of blonanserin.The population-predicted system apparent clearance (CL/F), volume of apparent distribution in center (V1/F) and first-order absorption rate constant (Ka) of blonanserin under fasting was 1230 L/h, 9500 L and 3.02 h-1 respectively.Food intake decreased Ka ofblonanserin to 0.78 h-1.The relative bioavailability between fasting and food intake estimated by the final model was 55%.No clinically significant safety issues were identified.Conclusion: This is the first study assessing the pharmacokinetic profile ofblonanserin with population pharmacokinetics method.The results can be used for simulation in further clinical trial and to optimize individual dosage regimens using a Bayesian methodology in patients.